An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP
A global COVID-19 program has targeted a supply deal for an outpatient antiviral pill by the end of November to secure at least 28 million courses of treatment, available from the first quarter of 2022, according to a draft document.
